TrumpRx Launches to Provide Recued Prices for Prescription Medicines in the U.S.
President Donald Trump has formally launched the TrumpRx website, a new platform designed to provide significantly reduced prices on prescription medicines for U.S. patients who pay in cash. The site offers access to more than 40 medications at discounted rates and operates as a direct-to-consumer (DTC) channel.
The TrumpRx initiative went live on Thursday, the 5 February 26, and features products from the first five pharmaceutical companies that agreed to pricing arrangements with the Trump Administration under the Most Favored Nation (MFN) policy. These manufacturers include AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk, and Pfizer.
Pfizer Lead Manufacturer Participation Under the MFN Pricing Agreements
Pfizer was the first major pharmaceutical company to reach a pricing agreement with the White House. As part of this commitment, the company agreed to make a broad selection of its medicines available at what it described as a “significant discount” through the TrumpRx.gov platform.
According to Pfizer’s press release, the global pharma giant launched its TrumpRx program on Thursday with 30 medicines included. The announcement stated that the products would be offered to self-paying consumers at discounts of up to 85%, with average reductions closer to 50%.
White House Announcemen Adressed Fifferences in Global Drug Pricing
During a White House event on 5 February, President Trump addressed longstanding differences in global drug pricing, stating:
“Americans have long been paying the highest drug prices anywhere in the world. While other countries often paid pennies on the dollar for the exact same drugs. We were essentially subsidising the entire world and subsidising by hundreds of billions of dollars every year.”
He also announced the immediate availability of discounted medicines through the new platform, adding:
“Starting tonight, dozens of the most commonly used prescription drugs will be available at dramatic discounts for all consumers through a new website called TrumpRx.gov”.
GLP-1 Weight-loss Blockbusters on TrumpRx
Some of the most notable discounts on TrumpRx.gov apply to glucagon-like peptide-1 receptor agonists (GLP-1RAs), which rank among the highest-spending drug classes in the United States. Eli Lilly and Novo Nordisk’s obesity treatments, Zepbound and Wegovy, stand out in particular. Combined, these weight loss medications generated more than $21bn in U.S. sales in 2025 alone.
Although the majority of U.S. residents have health coverage, research indicates that a substantial portion of the population continues to pay cash for prescriptions, despite having insurance for part or all of 2023. Around 60% of individuals reportedly paid out-of-pocket for prescription drugs in 2022.
More Headlines
